Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry

Akgül, Özgür; Bodur, Hatice; Ataman, Şebnem; Yurdakul, Fatma Gül; Çapkın, Erhan; Gürer, Gülcan; Sezer, İlhan; Duruöz, Mehmet Tuncay; Melikoğlu, Meltem Alkan; Çay, Hasan Fatih; Rezvanı, Aylin; Yağcı, İlker; Göğüş, Feride; Kamanlı, Ayhan; Çevik, Remzi

doi:10.1007/s00296-020-04680-8

Cited by 21 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current evidence suggests that sex/gender differences exist in terms of time to diagnosis [ 13 , 17 ], treatment outcomes [ 15 , 33 , 35 , 36 ] and HRQoL [ 45 – 47 ] in patients with axSpA. These differences may be related to biological factors such as differing genetic and immunological profiles [ 13 , 22 , 52 ], or social factors such as employment and marital status [ 13 , 49 , 58 ].…”

Section: Discussionmentioning

confidence: 99%

“…The clinical manifestations of axSpA that lead to reduced physical functioning and restricted participation in daily activities can result in impaired HRQoL and reduced lifesatisfaction [44]. Female gender has been disproportionately associated with impaired HRQoL in patients with axSpA, as reported using multiple tools such as the Short-Form (SF-36) Health Survey mental component score, ASQoL and the ASAS Health Index (ASAS HI) [45][46][47]. Many factors have been explored which could explain the impaired HRQoL reported in women, including fatigue, pain, sleep disturbances and increased disease activity, all of which have been reported to affect women more than men [48,49].…”

Section: Gender Differences In Hrqol Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis

Marzo‐Ortega

Navarro-Compán²,

Akar

et al. 2022

Clin Rheumatol

View full text Add to dashboard Cite

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic condition, historically considered a predominantly male disease. However, increasing evidence suggests a more equal prevalence between men and women. Of the limited research conducted to date, it is apparent that gender differences exist in terms of time to diagnosis, treatment outcomes and health-related quality of life (HRQoL). Despite this, women are underrepresented in clinical trials and most studies do not stratify by gender to identify potential differences in terms of disease manifestations and treatment response. In this perspectives article, we reflect on the potential biological and social factors contributing to these differences and propose three key areas of education and research that should be prioritised in order to address the unmet needs of female patients with axSpA, namely: (1) to identify ways to increase awareness of disease occurrence in female patients among healthcare professionals (HCPs), (2) to improve understanding of gender differences in disease manifestation and outcomes, and (3) to conduct gender-stratified clinical trials with a representative sample of female patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Gender Differences In Hrqol Outcomesmentioning

confidence: 99%

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis

Marzo‐Ortega

Navarro-Compán²,

Akar

et al. 2022

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…Este punto también fue evaluado en el estudio de Akgul y col., en el cual tampoco se observó diferencia en las puntuaciones medias de ASAS-HI entre los pacientes con EA y EspAax-nr. 10 Sin embargo, en el estudio de la Cohorte Católica de Espondiloartritis Axial (CASCO), una cohorte prospectiva de un solo hospital, los pacientes con EA presentaban mayor edad y tenían ASAS-HI más alto que los pacientes con EspAax-nr. 11 Tampoco encontramos diferencias en los valores medianos de ASAS-HI entre los pacientes con EspAax y EspAp.…”

Section: Discussionunclassified

“…[1][2] El ASAS-HI fue validado en varios países, 3-8 aunque hasta la fecha, se han publicado muy pocos estudios que evalúen el uso del ASAS-HI en la práctica clínica habitual en EspAax. [9][10][11] Este cuestionario fue validado en Argentina en el año 2017. 12 Por otro lado, fue escasamente evaluado de manera independiente en pacientes con EspAp.…”

Section: Introductionunclassified

ASAS Health Index performance in real-life Spondyloarthritis patients

Martire

Bosch

Airoldi

et al. 2021

Rev. Argent. Reumatol.

View full text Add to dashboard Cite

Introduction: the “Assessment of Spondyloarthritis International Society Health Index” (ASASHI) questionnaire was developed to globally measure function and health status in patients with spondyloarthritis (SpA). Cut-off points have been proposed to determine different health states that were poorly evaluated in real-life patients. Objectives: to describe the health status measured by ASAS-HI in Argentine patients with axial SpA (AxSpA) and peripheral SpA (SpAp) in daily practice and to evaluate the factors associated with poor health. Materials and methods: cross-sectional, analytical and multicenter study. Patients with SpAax and SpAp were consecutively included according to ASAS criteria, from 15 Argentine centers. Statistical analysis: descriptive statistics, bivariate and multivariate analysis (multiple logistic regression) were performed to evaluate the factors associated with poor health status (ASAS-HI≥12). To analyze the construct validity of the tool, Spearman correlation was performed between the ASAS-HI and other disease evaluation parameters. Results: 274 patients with SpA were included, with a mean age of 49 (± 14) years and a median duration of the disease of 62 months (p25-75: 24-135), 155 (56.6%) were male, 129 patients (47%) with AxSpA and 145 (52.9%) SpAp. According to the ASAS-HI, 119 patients (43.4%) had good health, 117 (42.7%) had moderate health and 38 (13.9%) had poor health. In patients with SpAp, the mean ASAS-HI value was 7 (p25-75: 3-10). The ASAS-HI positively correlated with: DAS28: rho: 0.5 (p <0.001) and HAQ: rho: 0.54 (p <0.001). The variable independently associated with poor health status was DAS28 (OR: 1.9, 95% CI 1.1-3.4, p: 0.029). In patients with AxSpA, the mean ASAS-HI value was 6 (p25-75: 2.75-10). The ASAS-HI showed correlation with: BASDAI: rho: 0.7 (p <0.001), ASDAS-ERS: rho: 0.7 (p <0.001), ASQoL: rho: 0.8 (p<0.001), BASFI rho: 0.75 (p <0.001) 0.001). The variable that was independently associated with poor health was the ASDAS-ERS (OR 6.6, 95% CI 2-22, p 0.002). Conclusion: poor health status was independently associated with higher disease activity in patients with AxSpA and SpAp. The ASAS-HI correlated with other parameters of the disease, which reinforces the construct validity of this new tool.

show abstract

“…Auch das CRP ist in der Regel nur geringfügig erhöht (z. B. wird ein Durchschnittswert von 8,2 mg/l ± 13,1 mg/l in einem großen Kollektiv von[27] angegeben). Das lange vertretene Dogma, dass eine AS stets mit einem positiven HLA-B27 assoziiert sein muss, ist nicht gültig.…”

unclassified

Diagnostik und Therapie der ankylosierenden Spondylarthritis – ein Update

Bornemann¹,

Randau²

2021

Orthopädie und Unfallchirurgie up2date

View full text Add to dashboard Cite

Clinical performance of ASAS Health Index in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: real-world evidence from Multicenter Nationwide Registry

Cited by 21 publications

References 29 publications

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis

ASAS Health Index performance in real-life Spondyloarthritis patients

Diagnostik und Therapie der ankylosierenden Spondylarthritis – ein Update

Contact Info

Product

Resources

About